Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review

• Published in: Modern rheumatology
• Main Authors: Sada, Ken-Ei, Miyamae, Takako, Kaneko, Kayoko, Isojima, Sakiko, Ichinose, Kunihiro, Matsushita, Masakazu, Oku, Kenji, Iwata, Yasunori, Fujio, Keishi, Murashima, Atsuko, Tanaka, Yoshiya, Nakajima, Ayako
• Format: Journal Article
• Language: English
• Published: England 06.08.2024
• Subjects: Cyclophosphamide; systemic lupus erythematosus; ovarian function; pediatrics; scoping review
• ISSN: 1439-7595; 1439-7609; 1439-7609
• DOI: 10.1093/mr/roae060

This systematic scoping review assess the effect of cyclophosphamide (CY) administration during childhood on ovarian function in patients with juvenile-onset connective tissue diseases. A MEDLINE database search was conducted using terms related to CY, juvenile-onset connective tissue diseases, and ovarian function. Studies were included if they met specific criteria. The search, conducted on 28 November 2023, yielded 3328 references. After a two-stage screening process, six observational studies on systemic lupus erythematosus patients were included. All studies had a high risk of confounding bias, as none adjusted for confounding variables. Two studies assessing clinical ovarian dysfunction found no clear difference between CY and non-CY groups. However, statistical differences were observed in hormonal profiles. Decreased ovarian reserve was more frequent in CY-exposed patients. Two studies showed significantly higher follicle-stimulating hormone (FSH) levels in the CY group, while one showed a trend towards higher FSH levels without statistical significance. This review suggested that CY use in childhood may not conclusively have clinically significant effects on ovarian function. Further investigation needed on CY's effect on hormonal levels, fertility, and pregnancy outcomes.